Positive and clinically meaningful pivotal clinical results announced in 2022 in both metastatic and locally…
Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with…
REDWOOD CITY, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (NASDAQ: JSPR), a…
BALTIMORE, Jan. 04, 2023 (GLOBE NEWSWIRE) — Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused…
NEW YORK and LONDON, Jan. 04, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX),…
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) — Sutro Biopharma, Inc. (Sutro or…
CBO-212 is a first-in-class inhibitor of CD73 cancer immunotherapy target SAN DIEGO, Jan. 04, 2023…
SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision…
MORRISVILLE, N.C., Jan. 04, 2023 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty…
– Product Revenues, Net Expected in the Range of $565.0 Million to $580.0 Million –…
CHARLOTTESVILLE, Va. and CARMEL, Ind., Jan. 04, 2023 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ:…
SALT LAKE CITY, Jan. 04, 2023 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a…
GERMANTOWN, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) — TeraImmune, Inc., a biotechnology company focused on…
WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical…
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage…
POTOMAC, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) — via InvestorWire — India Globalization Capital, Inc….
– The Expanded Access Program (EAP) allows physicians to request access to TransCon PTH, the…
NEW YORK, Jan. 04, 2023 (GLOBE NEWSWIRE) — LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient…
SYDNEY, AUSTRALIA, Jan. 04, 2023 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep”…
Dr. Susana Banerjee (The Royal Marsden NHS Foundation Trust, UK), will be the ENGOT and…